These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 25618296)
1. Increased expression of L-selectin (CD62L) in high-grade urothelial carcinoma: A potential marker for metastatic disease. Choudhary D; Hegde P; Voznesensky O; Choudhary S; Kopsiaftis S; Claffey KP; Pilbeam CC; Taylor JA Urol Oncol; 2015 Sep; 33(9):387.e17-27. PubMed ID: 25618296 [TBL] [Abstract][Full Text] [Related]
2. Implication of vascular endothelial growth factor A and C in revealing diagnostic lymphangiogenic markers in node-positive bladder cancer. Poyet C; Thomas L; Benoit TM; Delmo DA; Luberto L; Banzola I; Günthart MS; Sais G; Eberli D; Sulser T; Provenzano M Oncotarget; 2017 Mar; 8(13):21871-21883. PubMed ID: 28423532 [TBL] [Abstract][Full Text] [Related]
3. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer. Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769 [TBL] [Abstract][Full Text] [Related]
4. Expression and clinical significance of Centrosomal protein 55 (CEP55) in human urinary bladder transitional cell carcinoma. Singh PK; Srivastava AK; Rath SK; Dalela D; Goel MM; Bhatt ML Immunobiology; 2015 Jan; 220(1):103-8. PubMed ID: 25178936 [TBL] [Abstract][Full Text] [Related]
5. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage. Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643 [TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder. Dohn LH; Illemann M; Høyer-Hansen G; Christensen IJ; Hostmark J; Litlekalsoy J; von der Maase H; Pappot H; Laerum OD Urol Oncol; 2015 Apr; 33(4):165.e15-24. PubMed ID: 25575713 [TBL] [Abstract][Full Text] [Related]
7. High expression of polo-like kinase 1 is associated with the metastasis and recurrence in urothelial carcinoma of bladder. Zhang Z; Zhang G; Kong C Urol Oncol; 2013 Oct; 31(7):1222-30. PubMed ID: 22192978 [TBL] [Abstract][Full Text] [Related]
8. Sialosyl-Le(x) expression defines invasive and metastatic properties of bladder carcinoma. Numahata K; Satoh M; Handa K; Saito S; Ohyama C; Ito A; Takahashi T; Hoshi S; Orikasa S; Hakomori SI Cancer; 2002 Feb; 94(3):673-85. PubMed ID: 11857299 [TBL] [Abstract][Full Text] [Related]
9. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. King ED; Matteson J; Jacobs SC; Kyprianou N J Urol; 1996 Jan; 155(1):316-20. PubMed ID: 7490878 [TBL] [Abstract][Full Text] [Related]
10. Frequent expression of zinc-finger protein ZNF165 in human urinary bladder transitional cell carcinoma. Singh PK; Srivastava AK; Dalela D; Rath SK; Goel MM; Bhatt ML Immunobiology; 2015 Jan; 220(1):68-73. PubMed ID: 25214475 [TBL] [Abstract][Full Text] [Related]
11. A potential role for 6-sulfo sialyl Lewis X in metastasis of bladder urothelial carcinoma. Taga M; Hoshino H; Low S; Imamura Y; Ito H; Yokoyama O; Kobayashi M Urol Oncol; 2015 Nov; 33(11):496.e1-9. PubMed ID: 26137907 [TBL] [Abstract][Full Text] [Related]
12. Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile. Dip N; Reis ST; Timoszczuk LS; Viana NI; Piantino CB; Morais DR; Moura CM; Abe DK; Silva IA; Srougi M; Dall'Oglio MF; Leite KR J Urol; 2012 Nov; 188(5):1951-6. PubMed ID: 22999546 [TBL] [Abstract][Full Text] [Related]
13. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker. Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N Urol J; 2009; 6(2):101-8. PubMed ID: 19472128 [TBL] [Abstract][Full Text] [Related]
14. Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1. Rausch S; Hennenlotter J; Teepe K; Kuehs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Stenzl A; Schwentner C; Todenhöfer T Urol Oncol; 2015 Oct; 33(10):426.e21-9. PubMed ID: 26231311 [TBL] [Abstract][Full Text] [Related]
15. Expression of transcription factor Twist1 in bladder urothelial carcinoma and its clinical significance. Tang X; Xing J; Li W; Wu Z; Zhang K; Zheng J J BUON; 2013; 18(1):211-9. PubMed ID: 23613408 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of NANOG in urothelial carcinoma of the bladder. Md Akhir MKA; Hussin H; Veerakumarasivam A; Choy CS; Abdullah MA; Abd Ghani F Malays J Pathol; 2017 Dec; 39(3):227-234. PubMed ID: 29279584 [TBL] [Abstract][Full Text] [Related]
17. Comparison of multidrug resistance gene expression levels with malignant potentials and influence of chemotherapy in urothelial cancers. Kakehi Y; Wu WJ; Kim WJ; Arao S; Fukumoto M; Yoshida O Int J Urol; 1995 Nov; 2(5):309-15. PubMed ID: 8749949 [TBL] [Abstract][Full Text] [Related]
18. Clonal origin of lymph node metastases in bladder carcinoma. Jones TD; Carr MD; Eble JN; Wang M; Lopez-Beltran A; Cheng L Cancer; 2005 Nov; 104(9):1901-10. PubMed ID: 16196038 [TBL] [Abstract][Full Text] [Related]
19. Sp1 is overexpressed and associated with progression and poor prognosis in bladder urothelial carcinoma patients. Zhu J; Lu Z; Ke M; Cai X Int Urol Nephrol; 2022 Jul; 54(7):1505-1512. PubMed ID: 35467245 [TBL] [Abstract][Full Text] [Related]
20. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]